| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/07/2023 | 1270.67% | Cantor Fitzgerald | → $7 | Reiterates | Overweight → Overweight |
| 08/11/2023 | 1074.86% | Truist Securities | $8 → $6 | Maintains | Buy |
| 08/11/2023 | 879.05% | HC Wainwright & Co. | → $5 | Reiterates | Buy → Buy |
| 08/08/2023 | 1074.86% | Berenberg | → $6 | Assumes | → Buy |
| 06/05/2023 | 879.05% | HC Wainwright & Co. | $6 → $5 | Maintains | Buy |
| 05/24/2023 | 1074.86% | HC Wainwright & Co. | → $6 | Reiterates | Buy → Buy |
| 03/27/2023 | 1270.67% | Wells Fargo | → $7 | Assumes | → Overweight |
| 03/24/2023 | 95.81% | Stifel | $2 → $1 | Maintains | Hold |
| 03/24/2023 | 1074.86% | HC Wainwright & Co. | → $6 | Reiterates | → Buy |
| 12/12/2022 | 1270.67% | Wells Fargo | $8 → $7 | Maintains | Overweight |
| 12/12/2022 | 1074.86% | Piper Sandler | $7 → $6 | Maintains | Overweight |
| 12/12/2022 | 1074.86% | SVB Leerink | $10 → $6 | Maintains | Outperform |
| 12/12/2022 | 1074.86% | HC Wainwright & Co. | → $6 | Initiates Coverage On | → Buy |
| 10/10/2022 | 291.62% | Stifel | $9 → $2 | Downgrades | Buy → Hold |
| 06/23/2022 | 1662.29% | SVB Leerink | $10 → $9 | Maintains | Outperform |
| 03/31/2022 | 1270.67% | Piper Sandler | → $7 | Initiates Coverage On | → Overweight |
| 02/23/2022 | 2249.72% | Cantor Fitzgerald | → $12 | Initiates Coverage On | → Overweight |
| 10/21/2021 | 1858.1% | Truist Securities | → $10 | Initiates Coverage On | → Buy |
| 10/12/2021 | 2249.72% | SVB Leerink | $13 → $12 | Maintains | Outperform |
| 09/30/2021 | 2249.72% | Stifel | → $12 | Initiates Coverage On | → Buy |
| 03/31/2021 | 2837.15% | Credit Suisse | → $15 | Initiates Coverage On | → Outperform |
| 03/24/2021 | 2837.15% | Wells Fargo | $10 → $15 | Maintains | Overweight |
| 03/11/2021 | 2641.34% | SVB Leerink | $9 → $14 | Maintains | Outperform |
| 11/11/2020 | 1662.29% | SVB Leerink | $8 → $9 | Maintains | Outperform |
| 06/24/2020 | 1466.48% | SVB Leerink | $7 → $8 | Maintains | Outperform |
| 03/28/2019 | 1466.48% | SVB Leerink | → $8 | Initiates Coverage On | → Outperform |
What is the target price for Affimed (AFMD)?
The latest price target for Affimed (NASDAQ: AFMD) was reported by Cantor Fitzgerald on September 7, 2023. The analyst firm set a price target for $7.00 expecting AFMD to rise to within 12 months (a possible 1270.67% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Affimed (AFMD)?
The latest analyst rating for Affimed (NASDAQ: AFMD) was provided by Cantor Fitzgerald, and Affimed reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Affimed (AFMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Affimed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Affimed was filed on September 7, 2023 so you should expect the next rating to be made available sometime around September 7, 2024.
Is the Analyst Rating Affimed (AFMD) correct?
While ratings are subjective and will change, the latest Affimed (AFMD) rating was a reiterated with a price target of $0.00 to $7.00. The current price Affimed (AFMD) is trading at is $0.51, which is within the analyst's predicted range.